Aprea Therapeutics Q1 FY26 net loss narrows to $3.3 million

Aprea Therapeutics

Aprea Therapeutics

APRE

0.00
  • Aprea Therapeutics posted a Q1 net loss of USD 3.29 million, narrowing from USD 3.93 million a year earlier, while loss per share improved to USD 0.22 from USD 0.66.
  • Operating loss narrowed to USD 3.43 million from USD 4.09 million, as operating expenses fell to USD 3.43 million from USD 4.25 million.
  • R&D spend dropped to USD 1.61 million from USD 2.48 million, while cash and cash equivalents climbed to USD 46.5 million at March 31 from USD 14.6 million at Dec. 31.
  • An oversubscribed USD 30 million private placement closed March 31, with proceeds earmarked to expand APR-1051 enrollment; ACESOT-1051 has reported two partial responses among 28 treated patients, with dose escalation ongoing at 300 mg.
  • Management said APR-1051 data to date show encouraging tolerability, with additional ACESOT-1051 results slated for presentation at ASCO on May 30; cash runway expected into Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130630PRIMZONEFULLFEED9718606) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.